Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;16(5):434-40.
doi: 10.1097/MOO.0b013e32830ce796.

Issues, indications, and controversies regarding intratympanic steroid perfusion

Mohamed Hamid  1 , Dennis Trune
Affiliations
Review

Issues, indications, and controversies regarding intratympanic steroid perfusion

Mohamed Hamid et al. Curr Opin Otolaryngol Head Neck Surg. 2008 Oct.

Abstract

Purpose of review: Office-based intratympanic inner ear steroid perfusion (ITPs) treatment for Ménière's disease, autoimmune inner ear disease, and sudden sensorineural hearing loss has been expanding over the past 10-15 years, yet remains controversial. The purpose of this review is to examine the current literature of basic science and human studies of ITPs treatment.

Recent findings: Animal studies exist regarding the delivery, distribution, biochemical, and microbiological changes in the inner ear post ITPs. However, few clinical studies exist on ITPs treatment in sudden sensorineural hearing loss and even less in treating Ménière's disease. There are no consistent studies regarding drug delivery methods, type, and concentration of steroids. Moreover, there are no studies comparing ITPs results to the natural history of Ménière's disease.

Summary: ITPs has impacted otology and neurotology practice due to increased utilization. A sound understanding of the basic science and clinical studies is needed to establish long-term efficacy of ITPs in controlling hearing loss in Ménière's disease by comparison to its natural history, as well as, potential application to other disorders.

PubMed Disclaimer

References

    1. Sakata E, Kitago Y, Murata Y, Teramoto K. Treatment of Meniere’s disease. Middle ear infusion with lidocaine and steroid solution. Auris Nasus Larynx. 1986;13:79–89. - PubMed
    1. Shea JJ, Jr, Ge X. Dexamethasone perfusion of the labyrinth plus intravenous Dexamethasone for Meniere’s disease. Otolaryngol Clin North Am. 1996;29:353–358. - PubMed
    1. Alles MJ, der Gaag MA, Stokroos RJ. Intratympanic steroid therapy for inner ear diseases, a review of the literature. Eur Arch Otorhinolaryngol. 2006;263:791–797. - PubMed
    1. Conlin AE, Parnes LS. Treatment of sudden sensorineural hearing loss: I. A systematic review. Arch Otolaryngol Head Neck Surg. 2007;133:573–581. - PubMed
    1. Hoffer ME, Balough BJ, Gottshall KR. Delivery of drugs to the inner ear. Curr Opin Otolaryngol Head Neck Surg. 2006;14:329–331. - PubMed

MeSH terms